Blutwerte · Marker

Fibrinogen

Plasma Fibrinogen · Gerinnungsfaktor I

Entzündungsmarker

Einheit:: g/L
Abbreviation: Fib

Fibrinogen test quantifies the concentration of fibrinogen, a glycoprotein involved in blood clot formation.

Reference Ranges

Reference

2–4g/L

2.5

3.5

LowNormalHigh

Reference

Optimal

Unit · g/L

Reference ranges may vary slightly based on laboratory standards.

Overview

Übersicht

Fibrinogen, also known as Plasma Fibrinogen or Gerinnungsfaktor I, is a glycoprotein in the blood plasma that plays a crucial role in the coagulation process. It is converted by thrombin into fibrin during blood clot formation. Researchers have observed that fibrinogen levels can reflect various physiological and pathological states, making it a valuable biomarker in clinical settings. Clinically, fibrinogen is significant as it is involved in clot formation and is a marker for inflammation. Elevated levels are associated with conditions such as atherosclerosis, myocardial infarction, and venous thrombosis, while decreased levels can indicate bleeding disorders or liver dysfunction. For athletes and biohackers, fibrinogen levels may be of interest due to their role in recovery and inflammation, potentially impacting performance and longevity. However, the interpretation of fibrinogen levels can be confounded by factors such as acute phase reactions, time of day, and recent physical activity. Therefore, it is important to consider these variables when assessing fibrinogen levels.

Klinische Bedeutung
Elevated fibrinogen levels indicate increased risk of cardiovascular diseases and inflammation. Reduced levels suggest bleeding disorders or liver dysfunction.

Dynamics

Trend Interpretation

Rising Values

Progressively rising fibrinogen levels suggest increasing inflammation or cardiovascular risk. Retest in 3-6 months if elevated.

Falling Values

Progressively falling levels may indicate improved inflammation control or potential bleeding risk.

Re-test Interval

3-6 months if outside optimal range

Etiology

Causes — High & Low

Cause

Elevated Levels

Inflammation
Pregnancy
Smoking
Obesity
Acute infection

Cause

Low Levels

Liver disease
Disseminated intravascular coagulation
Genetic fibrinogen disorders
Severe malnutrition
Chronic liver disease

Protocol

How to Optimize

Lever

Lifestyle

Regular exercise
Smoking cessation
Weight management

Lever

Nutrition

Omega-3 fatty acids
High-fiber diet

Lever

Supplementation

Fish oil
Vitamin C

Note:

Consult a healthcare provider before making significant lifestyle changes, especially if underlying health conditions are present.

Testing Guidelines

✓Fasting Not Required

✓Not Time-Sensitive

Fibrinogen levels may vary throughout the day; morning tests are preferred for consistency.

Testing Frequency

Annually for individuals with cardiovascular risk factors.

Interfering Factors

Recent surgery
Acute infection
Pregnancy

Open Research Questions

Current research suggests that the optimal reference ranges for fibrinogen levels and the impact of genetic variants on fibrinogen function remain debated, particularly in conditions like pseudohomozygous dysfibrinogenemia. Researchers have not yet established the precise role of fibrinogen as a biomarker in various thrombotic conditions and its relationship with treatment outcomes. Additionally, clinical questions regarding the best management strategies for patients with fibrinogen abnormalities and the implications of fibrinogen levels in obstetric disseminated intravascular coagulation remain unanswered.

42 Research Publications

872

Total Citations

Human/RCT

3.3

Avg. Influence

2025

Latest

Sort

Filter

01Top

#01

Fibrinogen and Atherosclerotic Cardiovascular Diseases-Review of the Literature and Clinical Studies.

ReviewInfluence6.0

134

This review summarized the relationship between fibrinogen levels and atherosclerotic cardiovascular diseases (ASCVD). Researchers found that increased fibrinogen concentrations may indicate a higher risk of ASCVD and highlighted the need for further studies on its genetic and molecular modifications.

View on PubMed

02Top

#02

Laboratory diagnosis of dysfibrinogenemia.

ReviewInfluence6.0

121

Researchers reviewed the laboratory diagnosis of dysfibrinogenemia, a coagulation disorder linked to abnormal fibrinogen function. They outlined diagnostic tests and the importance of distinguishing between inherited and acquired forms of the disorder.

View on PubMed

03Top

#03

Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD.

HumanInfluence8.0

109

Researchers analyzed data to assess plasma fibrinogen as a biomarker for mortality and exacerbations in COPD patients. They found that high fibrinogen levels were associated with increased risks of hospitalizations and death, suggesting its potential role in clinical trials.

View on PubMed

#04

Laboratory and Genetic Investigation of Mutations Accounting for Congenital Fibrinogen Disorders.

ReviewInfluence4.0

This study reviewed congenital fibrinogen disorders, which can lead to bleeding issues. Researchers found that these disorders are caused by mutations in fibrinogen-encoding genes and can be classified into quantitative and qualitative deficiencies.

View on PubMed

#05

Defibrinogenating enzymes.

AnimalInfluence3.0

Researchers found that certain snake venoms can significantly reduce plasma fibrinogen levels through a proteolytic effect. The study highlighted the potential use of these venoms in coagulation studies, particularly in patients with conditions like stroke and thrombosis. However, further well-designed trials are needed to clarify their clinical applications.

View on PubMed

#06

Fibrinogen and aging.

Human

Researchers found that plasma fibrinogen levels increase with age, which may correlate with higher risks of cardiovascular diseases. The study highlighted that this increase is more pronounced than changes in blood glucose or cholesterol levels.

View on PubMed

#07

Laboratory testing for fibrinogen abnormalities.

ReviewInfluence1.0

Researchers summarized the importance of fibrinogen in clot formation and the implications of its disorders. They discussed various laboratory assays used to diagnose fibrinogen abnormalities, which can lead to increased bleeding risk.

View on PubMed

#08

Clotting factors: Clinical biochemistry and their roles as plasma enzymes.

ReviewInfluence2.0

Researchers described the coagulation process involving fibrinogen and its conversion to fibrin, which is crucial for blood clot formation. They emphasized the importance of laboratory testing for diagnosing bleeding and thrombotic disorders.

View on PubMed

#09

Potential Blood Biomarkers for Diagnosing Periprosthetic Joint Infection: A Single-Center, Retrospective Study.

HumanInfluence3.0

Researchers evaluated the effectiveness of various blood biomarkers, including fibrinogen, in diagnosing periprosthetic joint infection (PJI). They found that traditional biomarkers like C-reactive protein (CRP) outperformed fibrinogen in diagnostic accuracy.

View on PubMed

#10

Association between plasma fibrinogen and survival in patients with small-cell lung carcinoma.

HumanInfluence3.0

This study assessed the prognostic value of plasma fibrinogen levels in patients with small-cell lung carcinoma (SCLC). Researchers found that elevated fibrinogen levels were associated with poorer survival outcomes, indicating its potential as a prognostic biomarker.

View on PubMed

Clinical Trials (21)

Total Trials

5,700

Total Enrolled

Stability of Blood Clotting Products Stored in Emergency Ambulances Under Real-World Conditions

NCT07646964RECRUITING

Sponsor

Medical University of Graz

Enrollment

Started

2026

Primary outcome

Stability of fibrinogen concentrates and Octaplas LG AB During Storage Under Real-World EMS Conditions

ExanguinationTrauma Coagulopathy

Point of Care Fibrinogen Measurement in Trauma Patients in the Emergency Department

NCT07097337RECRUITING

Sponsor

Erasmus Medical Center

Enrollment

150

Started

2025

Primary outcome

Feasibility of qLabs Fib testing in the emergency department

Trauma Induced CoagulopathyTrauma CoagulopathyFibrinogen DeficiencyFibrinogen; Deficiency, AcquiredMassive Transfusion ProtocolMassive Hemorrhage

NCT06024486UNKNOWN

Sponsor

Assiut University

Enrollment

Started

2023

Primary outcome

The fibrinogen to albumin ratio

Juvenile Idiopathic Arthritis

Multidisciplinary Diagnosis and Treatment of Polycystic Ovary Syndrome

NCT06047574RECRUITING

Sponsor

Shanghai 10th People's Hospital

Enrollment

3,000

Started

2023

Primary outcome

Fibrinogen-like-protein 1 (FGL1)

Polycystic Ovary Syndrome

The CoAGulation Biomarkers and Atrial Fibrillation (COAG-AF) Pilot Study

NCT04947657RECRUITING

Sponsor

Tulane University

Enrollment

Started

2021

Primary outcome

Measure the change in Asymmetric dimethyl arginine (ADMA) in relation to atrial fibrillation burden

Atrial Fibrillation

Biomarkers in Rheumatoid Arthritis Treated With Anti-interleukin-6 Therapy

NCT04281602UNKNOWN

Sponsor

University Hospital, Caen

Enrollment

Started

2020

Primary outcome

Levels of usual biomarkers (C-reactive protein, fibrinogen, procalcitonin, serum protein electrophoresis)

Rheumatoid Arthritis

NCT02204852Phase 2COMPLETED

Sponsor

Sisse R. Ostrowski, MD PhD DMSc

Enrollment

Started

2014

Primary outcome

Mean change i plasma biomarkers reflecting endothelial damage

Septic Shock

Thromboembolic Complications After Pacemaker or Implantable Cardioverter-Defibrillator Procedures

NCT01717495UNKNOWN

Sponsor

University of Sao Paulo

Enrollment

Started

2013

Primary outcome

Thromboembolic complications

BradyarrhythmiasArrhythmiasCardiovascular DiseaseVenous ThrombosisPulmonary Embolism

Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency

NCT02065882Phase 3COMPLETED

Sponsor

Biotest

Enrollment

Started

2013

Primary outcome

Single-dose Pharmacokinetics (PK) of BT524: Terminal Elimination Half-life (t1/2) for Fibrinogen Antigen

Congenital AfibrinogenemiaCongenital Hypofibrinogenemia

Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)

NCT01694849Phase 2COMPLETED

Sponsor

Genfit

Enrollment

275

Started

2012

Primary outcome

Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis)

Non-Alcoholic Steatohepatitis (NASH)

Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.

NCT01541852Phase 2COMPLETED

Sponsor

Cambridge University Hospitals NHS Foundation Trust

Enrollment

Started

2012

Primary outcome

Vascular inflammation on FDG PET-CT

Chronic Obstructive Pulmonary Disease

28 Day Repeat Dose in Cystic Fibrosis Patients

NCT00903201Phase 2COMPLETED

Sponsor

GlaxoSmithKline

Enrollment

146

Started

2009

Primary outcome

Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

Cystic Fibrosis

A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers

NCT01010737Phase 1/2COMPLETED

Sponsor

BiondVax Pharmaceuticals ltd.

Enrollment

Started

2009

Primary outcome

To assess the safety, local and systemic tolerability and reactogenicity of Multimeric-001 vaccine when administered intramuscularly twice to elderly male and female subjects, using chemistry, CBC, fibrinogen, and urinalysis measurements.

Influenza

Publication Trend

Research publications about Fibrinogen over time

6total

'60

'72

'77

'17

'20

'21

Track your bloodwork in PepStack

Log lab results, track trends and optimize your biomarkers over time.

Download on theApp Store Get it onGoogle Play

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer